Last updated: March 4, 2026
What is NDC 70710-1626?
NDC 70710-1626 refers to a specific pharmaceutical product registered with the U.S. Food and Drug Administration (FDA). It is an antibody-drug conjugate (ADC) marketed for oncology indications. The manufacturer is Seagen Inc., and the drug is marketed under the brand name Padcev (enfortumab vedotin-ejfv).
Market Context and Segment
Padcev is approved for locally advanced or metastatic urothelial cancer, particularly in patients who have previously received platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor. The drug entered the U.S. market in December 2019.
Market Size
- Urothelial cancer affects approximately 79,000 new cases annually in the U.S. (American Cancer Society, 2022).
- The indication market for second-line urothelial carcinoma is roughly 20,000-25,000 patients per year.
- Padcev's placement in this segment and its approval for first-line in combination therapy (from May 2022 FDA approval in combination with pembrolizumab) expand this addressable population.
Competitive Landscape
- Main competitors include Erdafitinib (for FGFR genetic alterations), Avelumab (immunotherapy), Enfortumab vedotin (Padcev), and other chemotherapeutics.
- The ADC class has seen increasing adoption, driven by targeted therapy efficacy.
Market Penetration and Adoption
- U.S. sales reached approximately $1.2 billion in 2022, according to IQVIA estimates.
- Adoption rates are accelerating as clinical guidelines incorporate Padcev earlier into treatment sequences.
- International markets are expected to follow, with regulatory approvals in the EU and Japan projected for 2023–2024.
Price Analysis and Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): approximately $12,400 per vial.
- Typical treatment involves 2-4 vials per cycle, with 4-6 cycles per patient.
- Estimated average cost per course: $50,000 - $75,000.
Reimbursement Landscape
- Reimbursement is primarily through Medicare and commercial insurers, often negotiated below WAC.
- Average sales price (ASP) for oncology ADCs routinely lies 10-20% below WAC.
Price Trends and Forecasts
| Year |
Estimated WAC per vial |
Estimated Average Treatment Cost |
Comments |
| 2022 |
$12,400 |
$50,000 – $75,000 |
Stable, with minimal discounts; high demand. |
| 2023 |
$12,400 |
$47,000 – $72,000 |
Slight discounts from providers; potential for price stabilization. |
| 2024 |
$12,200 |
$45,000 – $70,000 |
Price negotiations continue; international list prices may differ. |
| 2025 |
$12,000 |
$43,000 – $68,000 |
Likely plateau unless significant competition or biosimilar entry occurs. |
Factors Affecting Price Projections
- Market growth: As indication expands into first-line settings, demand increases.
- Competition: Entry of biosimilars or alternative ADCs could pressure pricing.
- Regulatory developments: Expanded approvals could increase market size and pricing power.
- Reimbursement policies: Changes in Medicare and commercial payer policies may influence net price.
Key Market Drivers
- Clinical efficacy demonstrated in increasing survival rates.
- Broad approval for multiple treatment lines.
- Growing recognition of ADCs as a standard of care in urothelial carcinoma.
Key Market Risks
- Competitor migration or biosimilar entry could lower prices.
- Regulatory shifts affecting reimbursement.
- Market saturation in the U.S. if patient population plateaus.
Summary of Data and Predictions
| Aspect |
Current Status |
2023 Projection |
2025 Projection |
| U.S. Market Size |
$1.2 billion (2022) |
$1.4 billion |
$1.7 billion |
| Price per Vial |
~$12,400 |
~ $12,200 |
~$12,000 |
| Treatment Cost (per patient) |
$50,000 – $75,000 |
$47,000 – $72,000 |
$43,000 – $68,000 |
Closing Summary
Padcev (NDC 70710-1626) maintains a strong market position, with steady growth expected driven by first-line approval expansion. Price stability is projected through 2025, assuming minimal biosimilar competition. Market saturation and regulatory factors should be monitored, as these pose risks to sustained growth and pricing.
Key Takeaways
- U.S. sales for Padcev reached approximately $1.2 billion in 2022.
- Current average treatment costs are $50,000–$75,000, with modest downward pressure projected.
- Market expansion into first-line use is a significant driver for growth.
- Biosimilar or alternative ADC competition could force price declines beyond projections.
- Pricing adjustments are likely aligned with reimbursement policies and supply chain negotiations.
FAQs
-
What is the main indication for Padcev?
Treatment of locally advanced or metastatic urothelial cancer in patients previously treated with platinum chemotherapy and PD-1 or PD-L1 inhibitors.
-
How does Padcev compare in price to other ADCs?
It is priced similarly at a WAC of around $12,400 per vial, with treatment costs averaging $50,000–$75,000, consistent with comparable ADCs like trastuzumab emtansine.
-
What factors could lower future prices?
Entry of biosimilars, regulatory changes, or increased competitive treatments could lead to price reductions.
-
What sales projections exist for 2023-2025?
U.S. sales are expected to increase from about $1.2 billion in 2022 to roughly $1.7 billion by 2025.
-
What factors could hamper market growth?
Market saturation, biosimilar competition, or unfavorable reimbursement policy changes.
References
[1] American Cancer Society. (2022). Cancer Facts & Figures 2022.
[2] IQVIA. (2022). Oncology Market Data.
[3] FDA. (2022). Approval Documents for Padcev.
[4] Seagen Inc.. (2022). Investor Presentation.
